LEXOPAM

One of the benzodiazepines that is used in the treatment of anxiety disorders.

It is a Schedule Intravenous drug in the U.S. and Canada and under the Convention on Psychotropic Substances.

It is a intermediate-acting benzodiazepine.

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol.

• and opiate-withdrawal.

Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties.

It does not possess any antidepressant qualities.

Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence.

According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.

Receptor Positive allosteric modulator

GABA(A) Receptor Benzodiazepine Binding Site Ligand.

Bioavailability is 84% following oral administration.

The time to peak plasma level is 1-4 hours.

Bromazepam is generally well absorbed after oral administration.

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes).

One of the main metabolites is 3-hydroxybromazepam.

It is pharmacologically active and the half life is similar to that of the parent compound.

Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.

View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.